目前的临床范式和治疗进步在胸膜恶性瘤:一个叙事审查
Douglas Dias E Silva1, Beatriz Viesser Miyamura1, Isa Mambetsariev2
1Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, São Paulo 05652-900, SP, Brazil.
Cancers
|November 27, 2025
概括
胸膜上皮瘤 (TETs) 是罕见的,阻碍了治疗的进展. 本综述涵盖了TET组织学,分子亚型和新兴疗法,如免疫疗法和向药物.
科学领域:
- 在瘤学瘤学.
- 瘤生物学 瘤生物学
背景情况:
- 胸膜上皮瘤 (TETs) 是一种罕见的恶性瘤,起源于胸膜上皮细胞.
- 它们的稀有性给临床试验招生和治疗开发带来了重大挑战.
- 历史上的治疗包括手术,放射治疗和化疗,由于瘤异质性和缺乏可操作突变,进展有限.
研究的目的:
- 审查TETs的组织学和分子亚型.
- 讨论TETs当前的治疗环境.
- 突出正在研究的有前途的新疗法.
主要方法:
- 对胸膜上皮瘤的文献综述.
- 分析当前的治疗标准和正在进行的临床试验.
- 评估新兴的治疗方式.
主要成果:
- TETs表现出显著的组织学和分子多样性.
- 免疫疗法,氨酸激酶抑制剂和HITHOC的创新正在改变治疗方法.
- 目前,一些新型药物正在对TET进行临床试验.
结论:
- 了解TET异质性对于有效治疗至关重要.
- 新的治疗策略为TET患者提供了更好的治疗结果.
- 持续的研究和临床试验对于推进TET管理至关重要.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


